药明 康德内容团队编辑. Sarepta Therapeutics今日宣布与Arrowhead Pharmaceuticals达成一项全球独家许可和合作协议。根据协议，Sarepta将获得多个处于临床期 ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta's purchase of Arrowhead common stock at $27.25 per share. Over the next five years, ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three ...

Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta’s purchase of Arrowhead common stock at $27.25 per share. Over the next five years, Arrowhead is set ...

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...

In addition, Sarepta and Arrowhead have entered into a discovery collaboration for up to six additional muscle, cardiac, and/or CNS targets, using Arrowhead’s novel delivery technologies. As part of ...

Arrowhead is also eligible for up to $10 billion in potential milestones and low double-digit royalties. Needham lowered Sarepta’s price target to $202 from $205, maintaining a ‘Buy’ rating.

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...

Sarepta will also send Arrowhead $50 million a year for the next five years. Under the deal, Arrowhead will complete the Phase 1/2 trials underway for the four clinical-stage drugs, ...